Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.

Hepatology (Baltimore, Md.) - 1 Sept 1996

Tipples G A, Ma M M, Fischer K P, Bain V G, Kneteman N M, Tyrrell D L

Abstract excerpt

The (-) enantiomer of 3'-thiacytidine (lamivudine) has been found to be a potent inhibitor of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) replication. Mutation of methionine to valine or isoleucine at the YMDD (tyrosine, methionine, aspartate, aspartate) motif of the HIV reverse transcriptase has been shown to be responsible for lamivudine resistance in HIV. The hepadnaviruses also have the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Sequence
Share to Conserved Sequence
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Hepatitis B virus

Share to Molecular Sequence Data

Share to Mutation

Share to RNA, Viral

Source

Identifiers

PMID: 8781348
DOI: 10.1002/hep.510240340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.PMID 8781348Read ↗

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivoSemantic proximity Read ↗

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Semantic proximity Read ↗

Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.Semantic proximity Read ↗

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.Semantic proximity Read ↗

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.Semantic proximity Read ↗

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.Semantic proximity Read ↗

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.Semantic proximity Read ↗

Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.Semantic proximity Read ↗

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.Semantic proximity Read ↗

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.Semantic proximity Read ↗

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Semantic proximity Read ↗

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.